Tolerability of recombinant-methionyl hu
β
V. Chaudhry; M. Giuliani; B.G. Petty; D. Lee; M. Seyedsadr; D. Hilt; D.R. Cornbl
π
Article
π
2000
π
John Wiley and Sons
π
English
β 105 KB
This phase I, double-blind, randomized, placebo-controlled study evaluated the safety of single and multiple (daily for 7 days) subcutaneous administrations of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy human volunteers at seven doses, ranging from 3 to 500 Β΅g/kg/day. No seri